grade
pharmaceutical primary standard
agency
EP Reference Standard
API family
isoniazid
manufacturer/tradename
EDQM
mp
171-173 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
NNC(=O)c1ccncc1
InChI
1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
InChI key
QRXWMOHMRWLFEY-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Isoniazid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
针对结核菌的抗生素，抑制分枝菌酸的生物合成。由肝脏 N-乙酰转移酶 (NAT) 和 细胞色素 P450 2E1 (CYP2E1) 代谢形成肝毒素。选择性诱导 CYP2E1 的表达。可逆抑制 CYP2C19 和 CYP3A4 的活性，在临床相关浓度下机械性地灭活 CYP1A2、CYP2A6、CYP2C19 和 CYP3A4。
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 异烟肼
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Skin Irrit. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
Kanchan Ajbani et al.
Antimicrobial agents and chemotherapy, 59(1), 414-420 (2014-11-05)
Reliable molecular diagnostics, which detect specific mutations associated with drug resistance, are promising technologies for the rapid identification and monitoring of drug resistance in Mycobacterium tuberculosis isolates. Pyrosequencing (PSQ) has the ability to detect mutations associated with first- and second-line
Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.
Dick Menzies et al.
PLoS medicine, 6(9), e1000150-e1000150 (2010-01-28)
Laura Muñoz et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 60(3), 349-356 (2014-10-15)
The extent to which anti-tumor necrosis factor (TNF)-associated tuberculosis can be prevented is unclear, and there is no established guidance on the optimal screening strategy for latent tuberculosis (LTBI) in patients about to start anti-TNF therapy. We aimed to determine
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| I0500000 | 04061833837436 |